Comparative Pharmacology
Head-to-head clinical analysis: BUTRANS versus DURAGESIC 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTRANS versus DURAGESIC 12.
BUTRANS vs DURAGESIC-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
None Documented
None Documented
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic